NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
Clinical Trials
24 trialsNCT01897441 2024-12-24
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
Albert Einstein College of Medicine
Phase NA Terminated
NCT05065411 2024-02-26
VERU-024
Veru Inc.
Phase 3 Terminated
NCT04460807 2024-02-12
EXPERT
Ente Ospedaliero Ospedali Galliera
Phase 3 Terminated
NCT04869943 2024-01-26
ARTEST
Veru Inc.
Phase 3 Terminated
NCT01303679 2023-09-06
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Phase 3 Terminated
NCT02990845 2023-02-22
PEER
National Taiwan University Hospital
Phase 1/2 Terminated
NCT03874325 2022-05-31
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03220178 2022-01-06
PRECYCLE
Palleos Healthcare GmbH
Phase 4 Terminated
NCT00905021 2020-07-24
EXTENT
Baylor Breast Care Center
Phase 1/2 Terminated
NCT01627067 2020-06-19
Exemestane-RAD001-Metformin
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02983604 2019-08-07
GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
Gilead Sciences
Phase 1/2 Terminated
NCT01484041 2018-02-09
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
Georgetown University
Phase 1/2 Terminated
NCT00684216 2017-09-14
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
The Netherlands Cancer Institute
Phase 2/3 Terminated
NCT00194792 2017-07-11
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
University of Washington
Phase 2 Terminated
NCT00066807 2016-10-28
PERCHE
ETOP IBCSG Partners Foundation
Phase 3 Terminated
NCT00573755 2016-02-05
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Terminated
NCT00372996 2015-10-28
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
Pfizer
Phase 2 Terminated
NCT01149356 2015-05-25
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00674557 2013-07-10
Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00793546 2012-11-05
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer
Pfizer
Phase 2 Terminated
NCT00040014 2012-02-16
Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women
Pfizer
Phase 2 Terminated
NCT00417885 2010-09-21
A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
Pfizer
Phase 1/2 Terminated
NCT00810706 2008-12-18
ATENA
Hellenic Breast Surgeons Society
Phase 3 Terminated